FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
Season 5, Episode 5, Mar 15, 03:45 PM
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.